MannKind Corporation
MNKD · Price history
Price at last available close
$3.29
−$0.06 (-1.79%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About MannKind Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U. S.
How they make money
MannKind generates revenue through the commercialization of its own cardiometabolic products, including Afrezza, Furoscix, and V-Go, and through a collaboration with United Therapeutics for the orphan lung disease product Tyvaso DPI. The company earns revenue from product sales, royalties on net sales of licensed products, and manufacturing services provided to its collaboration partners.
Products & services
Afrezza (insulin human) Inhalation Powder for diabetes, Furoscix (furosemide injection) for heart failure, V-Go wearable insulin delivery device, and Tyvaso DPI (treprostinil) inhalation powder for pulmonary arterial hypertension and PH-ILD.
Brands & revenue mix
Ultra rapid-acting inhaled insulin for diabetes.
Separate brand revenue is not available in this research.Source
Inhaled treprostinil for pulmonary arterial hypertension.
Separate brand revenue is not available in this research.Source
On-body infusor for furosemide delivery.
Separate brand revenue is not available in this research.Source
Wearable insulin delivery device.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Disclosed major customers
- United Therapeutics CorporationSource
Customer concentration
The company reports significant revenue concentration from United Therapeutics Corporation, which accounted for a substantial portion of total revenue for the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party manufacturers for the production of certain components and finished drug products; specific supplier names are not disclosed.Source
Business relationships & partnerships
Competitors
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly EPS turned negative at -0.06 versus 0.00 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Total debt increased 606.6% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
34
Poor
Financial Strength
24
Business Quality / Moat
25
Management
50
Growth Quality
50
Risk / Durability
28
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
22
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
35/100
Building Historical Record
Model Score 35/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Asset quality scores strongly
- •Recent buyback activity is present
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for MNKD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can MNKD maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is MNKD's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is MNKD's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for MNKD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify MNKD's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
22
Market Cap
$1.06B
P/E Ratio
-27.2
EPS
$-0.14
52-Week High
$6.51
52-Week Low
$2.23
Beta
1.10
Analyst Target
$8.50
Shares Outstanding
314.1M
Total Revenue
$393.6M
Total Debt
$330.8M
Dividend
No current dividend
Liquidation Value / Share
$-0.21
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for MNKD
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Elevated debt risk
Negative shareholder equity • Total debt is at least one year of revenue • Cash covers less than 20% of total debt
Community Sentiment
0 active · 0 total callsNo personal call yet on MNKD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Technosphere drug-delivery platform.
- +Established commercial infrastructure for cardiometabolic products.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Debt risk (elevated): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Cash covers less than 20% of total debt.
- −Dependence on collaboration partners for revenue and product success.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
25
Oct 1, 2026
Change
+0.1
points
Current Score
25
Oct 5, 2026
Category Changes
MNKD increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
17
Projected Change
-7.6 points
Preliminary comparable-period financial changes suggest decline of approximately 7.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$3.29
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $393.6M | $349.0M | $285.5M | $199.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $95.7M | $61.2M | $76.6M | $62.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $297.9M | $287.8M | $208.9M | $136.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $76.9M | $66.3M | $45.9M | $31.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $199.9M | $144.1M | $94.3M | $94.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $290.2M | $249.0M | $136.3M | $127.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $30.7M | $27.5M | $77.5M | $15.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $7.8M | $38.8M | $72.6M | $8.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $44.8M | $13.8M | $38.0M | $25.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$48.7M | $1.4M | $30.5M | -$10.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$5.0M | -$4.5M | $2.9M | $1.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$43.6M | $5.9M | $27.6M | -$11.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.14 | $0.02 | $0.10 | $-0.04 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 309M | 306M | 274M | 267M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 309M | 314M | 284M | 267M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$109.4M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.06
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+606.6%
Cash Change
-7.2%
Margin Change
-18.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth. Pressure indicators included EPS growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 42.9%. EPS declined 2957.1%. Cash declined 7.2%. Total debt increased 606.6%. Net income margin declined by 18.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
Rumor Mill · MNKD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial